Home » Newsletters » BioWorld Science

BioWorld Science

June 30, 2010

View Archived Issues

GSK-1362885 is safe in healthy volunteers and patients with type 2 diabetes

REGN-88 well tolerated and reduces inflammation in phase I trials

Portland State University and DesignMedix claim new antimalarials

ArQule describes new RAF kinase inhibitors

Abbott identifies new kinase inhibitors

Palatin Technologies claims new melanocortin receptor ligands

SOX-9 implicated in chronic pancreatitis

MCP-1 is a potential biomarker for atherosclerosis in obese subjects

CP-870893/gemcitabine combination is safe in pancreatic cancer

First-in-human data reported on anticancer agent PF-337210

Raptor begins enrollment in phase III DR Cysteamine trial in nephropathic cystinosis

Aeterna Zentaris and Almac to develop companion diagnostic for AEZS-108 cancer therapy

Chelsea initiates phase III trial of Northera

Upsher-Smith acquires Ikano's ITI-111 for management of acute repetitive seizures

MORAb-022 cleared to enter phase I in the Netherlands

Stallergenes reports persistent efficacy of Actair in second year of phase IIb/III trial

Quark Pharmaceuticals reports results for QPI-1007 in glaucoma model

First patient receives CRMD-001 in phase II trial

Pipeline overview presented for TapImmune

EpiCept submits NDA for Ceplene in AML to FDA, requests priority review

DepoMed's NDA filing for DM-1796 triggers milestone payment from Abbott

Radiprodil does not meet primary endpoint in phase II trial in diabetic peripheral neuropathic pain

Aestus to develop Astellas' FK-614 as ATx-08-001 for neuropathic pain

Sanofi-aventis signs agreement for acquisition of TargeGen

NeuroSearch claims new nicotinic acetylcholine receptor ligands

Chelsea provides update on phase II study of CH-4051

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 8, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...